普鲁卡因
微透析
医学
利多卡因
药代动力学
麻醉
生物等效性
体内
药理学
局部麻醉剂
全身给药
外科
瘀伤
生物利用度
皮肤病科
间质液
打开标签
化学
作者
Katrin Tiffner,Tannaz Ramezanli,Beate Boulgaropoulos,Thomas Birngruber,Manfred Bodenlenz,Bettina Lackner,Reingard Raml,Sam G. Raney,Frank Michael Sinner
标识
DOI:10.1016/j.ejps.2026.107673
摘要
Background Cutaneous pharmacokinetics (PK) can be assessed using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD). However, the dermal vasculature can clear and redistribute compounds to the skin, which may affect an assessment of bioequivalence (BE). Objective This study verified the BE of a topical cream product to itself under high-dose conditions, evaluated the impact of systemic redistribution on BE assessment, and compared the performance of dOFM and dMD. Methods In this open-label exploratory clinical study, 15 dOFM and 6 dMD probes were inserted in each of 20 healthy subjects at three treated sites on each thigh, and one untreated site on the arm. Systemic redistribution was assessed by comparing lidocaine and prilocaine AUC 0to12h at untreated versus treated sites, which collectively received 60 g of EMLA cream (lidocaine/prilocaine 2.5%/2.5%) applied across 400 cm 2 per subject. The performance of dOFM and dMD was compared using dermal PK parameters and data variability. Applying a reference-scaled approach, BE was assessed using dOFM-derived logAUC 0to12h and logC max , both, with and without correction for systemic redistribution. Results The BE of EMLA to itself was confirmed using dOFM and was unaffected by systemic redistribution; despite the high dose and large treatment surface area, dOFM AUC 0to12h values of untreated sites were ≤ 0.52% of treated sites . Under the standardized conditions of this study, dOFM and dMD exhibited comparable dermal PK profile characteristics. Conclusions Systemic redistribution was negligible and did not alter the BE assessment. Under standardized conditions, dOFM and dMD showed comparable PK profile characteristics, supporting the potential utility of both dOFM and dMD for characterizing the dermal PK of moderately lipophilic, protein-bound topical drugs under standardized study conditions. ClinicalTrials.gov registration NCT03813030.
科研通智能强力驱动
Strongly Powered by AbleSci AI